case_images: PMC6024047_01
case_images: Maximum intensity projection (MIP), axial, sagittal, and coronal F-18 FDG PET/CT images before ATT; MIP image (A) demonstrated diffusely increased FDG uptake throughout the stomach. Axial (B), sagittal (C), and coronal (D) PET/ CT images showed intense FDG uptake in the thickened gastric wall, and intra-abdominal enlarged lymph nodes
case_images: ejohg-08-093-g001.jpg
case_images: PMC6024047_01_ejohg-08-093-g001.jpg
case_images: F1
case_images: F-18 FDG PET/ CT revealed multiple hypermetabolic malignant lymphadenopathies at gastrohepatic, gastrosplenic, celiac, superior mesenteric, peripancreatic and hepatobiliary region, and paragastric region in size as 18 x 15 mm (SUVmax: 12.3) and diffuse gastric wall thickening as linitis plastica (SUVmax: 13.3), multiple hypermetabolic peritoneal implants in the omentum (SUVmax: 5.7) and peritoneum, and mild hypermetabolic suspected malignant lymph nodes at left supraclavicular region (Fig. 1).
case_images: Gastric ulcer on incisura angularis
case_images: ejohg-08-093-g002.jpg
case_images: PMC6024047_01_ejohg-08-093-g002.jpg
case_images: F2
case_images: Gastric ulcer at incisura angularis was detected on upper GI endoscopy (Fig. 2).
case_images: Langhans-type giant cells (black arrow), granulomas composed of epithelioid histiocytes (red arrow) (H&E 200*)
case_images: ejohg-08-093-g003.jpg
case_images: PMC6024047_01_ejohg-08-093-g003.jpg
case_images: F3
case_images: Histopathology of the lymph nodes extracted by exploratory laparotomy revealed granulamatous lymphadenitis with granulomas including giant cells, mostly suspecting TB (Fig. 3).
case_images: Follow-up F-18 FDG PET/CT images [maximum intensity projection (A), axial (B), sagittal (C), and coronal (D)] exhibited complete response to ATT with no residual disease
case_images: ejohg-08-093-g004.jpg
case_images: PMC6024047_01_ejohg-08-093-g004.jpg
case_images: F4
case_images: The F-18 FDG PET/ CT images (maximum intensity projection, CT, and fusion PET/ CT) exhibited a complete response to ATT with no residual disease (Fig. 4).